Corcept Therapeutics Receives Positive CHMP Opinion for Lifyorli in EU

Key Facts

1Corcept Therapeutics announced that the CHMP has recommended the European Commission approve relacorilant (Lifyorli) for marketing authorization.

In a move reflecting the regulatory momentum within the biotechnology sector, Corcept Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for relacorilant. The committee recommended that the European Commission grant marketing authorization for the drug, branded as Lifyorli, in the European Union. This recommendation serves as a critical regulatory milestone for the treatment, which is designed to address severe endocrinologic and metabolic disorders.

This development comes as specialized pharmaceutical firms seek to broaden their global footprint, with the European market representing a strategic growth opportunity for Corcept. According to market data, CORT stock closed at $114.86 on September 17, 2026, having traded between a day high of $115.09 and a day low of $111.07. These price levels underscore investor sensitivity to regulatory breakthroughs that enable the commercialization of proprietary therapies in major international jurisdictions.

Market participants should now look toward the final decision from the European Commission, which typically aligns with CHMP recommendations. Regarding broader regional catalysts, the market recently processed a speech by ECB President Christine Lagarde on September 14, 2026, providing context for the European economic environment. With CORT priced at $114.86 (close September 17, 2026), regulatory approvals remain the primary catalyst for the company's valuation outlook.